Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Deferred Taxes (2017 - 2023)

BeOne Medicines (BEIGF) has disclosed Deferred Taxes for 7 consecutive years, with -$46000.0 as the latest value for Q4 2023.

  • Quarterly Deferred Taxes fell 102.74% to -$46000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $689000.0 through Dec 2023, down 66.54% year-over-year, with the annual reading at $9.5 million for FY2025, 63.56% down from the prior year.
  • Deferred Taxes for Q4 2023 was -$46000.0 at BeOne Medicines, down from $750000.0 in the prior quarter.
  • The five-year high for Deferred Taxes was $14.8 million in Q3 2021, with the low at -$12.3 million in Q1 2021.
  • Average Deferred Taxes over 5 years is -$142300.0, with a median of -$48500.0 recorded in 2023.
  • The sharpest move saw Deferred Taxes tumbled 5847.09% in 2021, then surged 941.67% in 2022.
  • Over 5 years, Deferred Taxes stood at $4.1 million in 2019, then skyrocketed by 119.97% to $9.0 million in 2020, then tumbled by 89.99% to $903000.0 in 2021, then skyrocketed by 85.94% to $1.7 million in 2022, then plummeted by 102.74% to -$46000.0 in 2023.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at -$46000.0, $750000.0, and -$51000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.